187 related articles for article (PubMed ID: 21509689)
21. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Kneppers E; van der Holt B; Kersten MJ; Zweegman S; Meijer E; Huls G; Cornelissen JJ; Janssen JJ; Huisman C; Cornelisse PB; Bruijnen CP; Emmelot M; Sonneveld P; Lokhorst HM; Mutis T; Minnema MC
Blood; 2011 Sep; 118(9):2413-9. PubMed ID: 21690556
[TBL] [Abstract][Full Text] [Related]
23. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
24. Initial treatment of transplant candidates with multiple myeloma.
Moreau P; Touzeau C
Semin Oncol; 2013 Oct; 40(5):585-91. PubMed ID: 24135403
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
Koehne G; Giralt S
Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
[TBL] [Abstract][Full Text] [Related]
26. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.
Michallet M; Sobh M; El-Cheikh J; Morisset S; Sirvent A; Reman O; Cornillon J; Tabrizi R; Milpied N; Harousseau JL; Labussière H; Nicolini FE; Attal M; Moreau P; Mohty M; Blaise D; Avet-Loiseau H
Exp Hematol; 2013 Dec; 41(12):1008-15. PubMed ID: 23994781
[TBL] [Abstract][Full Text] [Related]
27. How to treat a newly diagnosed young patient with multiple myeloma.
San-Miguel JF; Mateos MV
Hematology Am Soc Hematol Educ Program; 2009; ():555-65. PubMed ID: 20008240
[TBL] [Abstract][Full Text] [Related]
28. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
29. Role of autologous and allogeneic stem cell transplantation in myeloma.
Bensinger WI
Leukemia; 2009 Mar; 23(3):442-8. PubMed ID: 19277049
[TBL] [Abstract][Full Text] [Related]
30. Role of autologous stem cell transplantation in multiple myeloma.
Kumar S
Curr Hematol Malig Rep; 2007 May; 2(2):121-7. PubMed ID: 20425360
[TBL] [Abstract][Full Text] [Related]
31. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
32. Second autologous transplant as salvage therapy in multiple myeloma.
Atanackovic D; Schilling G
Br J Haematol; 2013 Dec; 163(5):565-72. PubMed ID: 24111632
[TBL] [Abstract][Full Text] [Related]
33. [Hematopoietic stem cell transplantation in multiple myeloma].
Vela-Ojeda J; Ruiz-Esparza MA
Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
[TBL] [Abstract][Full Text] [Related]
34. In pursuit of the graft-versus-myeloma effect: a single institution experience.
Galo-Hooker EG; Ruiz-Delgado GJ; Zamora-Ortiz G; Velazquez-Sanchez-de-Cima S; Ruiz-Arguelles GJ
Hematology; 2013 Mar; 18(2):89-92. PubMed ID: 23320939
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic transplantation in multiple myeloma.
Gahrton G; Krishnan A
Expert Rev Hematol; 2014 Feb; 7(1):79-90. PubMed ID: 24224804
[TBL] [Abstract][Full Text] [Related]
36. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
37. [Allogeneic hematopoietic stem cell transplantation for multiple myeloma].
Takase K; Miyamoto T
Nihon Rinsho; 2015 Jan; 73(1):107-13. PubMed ID: 25626314
[TBL] [Abstract][Full Text] [Related]
38. [Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].
Vokurka S
Klin Onkol; 2010; 23(4):242-4. PubMed ID: 20806822
[TBL] [Abstract][Full Text] [Related]
39. Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.
Kröger N
Leukemia; 2007 Sep; 21(9):1851-8. PubMed ID: 17568819
[TBL] [Abstract][Full Text] [Related]
40. The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Leukemia; 2006 Oct; 20(10):1683-9. PubMed ID: 16888617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
